ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CARA Cara Therapeutics Inc

0.3631
-0.0053 (-1.44%)
Last Updated: 16:22:20
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cara Therapeutics Inc NASDAQ:CARA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0053 -1.44% 0.3631 0.3634 0.3677 0.368 0.355 0.3573 139,435 16:22:20

Cara Therapeutics to Webcast Presentation at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference

13/03/2015 12:00pm

GlobeNewswire Inc.


Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Cara Therapeutics Charts.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, March 20, 2015, at 2:00 p.m. ET in New York City.

A live webcast of the presentation can be accessed under "Events and Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

CONTACT: INVESTOR CONTACT:
         Jesse Baumgartner
         Stern Investor Relations, Inc.
         212-362-1200
         Jesse@sternir.com
         
         MEDIA CONTACT:
         Annie Starr
         6 Degrees
         973-415-8838
         astarr@6degreespr.com

1 Year Cara Therapeutics Chart

1 Year Cara Therapeutics Chart

1 Month Cara Therapeutics Chart

1 Month Cara Therapeutics Chart

Your Recent History

Delayed Upgrade Clock